According to the company, the new product is shipped as a flow-through and will be available at all existing retailers, including major drugstores CVS, Walgreens and Rite-Aid, mass retailers such as Walmart and Target as well as grocery chains including Publix and Safeway.
Kerasal Nail is used to treat nail disease and is also sold under the names Naloc/Nalox and Emtrix.
The company said that current distribution of Kerasal Nail is estimated to more than 30,000 outlets in the US.
The company’s new formula will offer benefits to consumers by improving user-friendliness, facilitating nail penetration and improving stability.
Moberg Pharma has applied for patent protection for the new product and the projected expiry date for this new IP is in 2034.
Moberg Pharma CEO Peter Wolpert said the new and improved Kerasal Nail demonstrates the value of our development approach, which continues to deliver innovative products with unique benefits to consumers.
"The new patent application can provide long term IP protection for our lead product," Wolpert said.